Additive benefits of EFAs in dogs with atopic dermatitis after partial response to antihistamine therapy.
It has been reported that 20 to 70 per cent of atopic cases in the dog can be controlled with antihistamines, though the effective antihistamine cannot be predetermined. Combination therapy with essential fatty acids (EFAs) and antihistamines has been shown to be useful in dogs. All of the work published to date has been performed in open studies, without the use of placebo, and in dogs where the aim has been to control pruritus as a symptom rather than that caused specifically by atopy. The aim of this study was to assess the combined effects of four antihistamines; hydroxyzine, chlorpheniramine, cyproheptadine and clemastine; with both an EFA supplement and a placebo of olive oil, in 25 dogs to control pruritus in clinically proven cses of atopy.
Paterson
S
S
Animal Medical Centre, Chorlton, Manchester.
D000818:Animals; D002744:Chlorpheniramine / Q000592:standards / Q000627:therapeutic use; D002974:Clemastine / Q000592:standards / Q000627:therapeutic use; D003533:Cyproheptadine / Q000592:standards / Q000627:therapeutic use; D003876:Dermatitis, Atopic / Q000188:drug therapy / Q000503:physiopathology / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy* / Q000503:physiopathology; D004285:Dogs; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005228:Fatty Acids, Essential / Q000592:standards / Q000627:therapeutic use*; D005260:Female; D006634:Histamine H1 Antagonists / Q000592:standards / Q000627:therapeutic use*; D006919:Hydroxyzine / Q000592:standards / Q000627:therapeutic use; D008297:Male; D012720:Severity of Illness Index
D005228:Fatty Acids, Essential; D006634:Histamine H1 Antagonists; D003533:Cyproheptadine; D006919:Hydroxyzine; D002744:Chlorpheniramine; D002974:Clemastine